linjc16/ctgov huggingface dataset:
Phase II Dose-Ranging Study of OrthoDerm Patch for Patients With Tennis Elbow

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effectiveness and safety of the use of low-dose nitroglycerin transdermal patches to treat pain and function in chronic tennis elbow.

Detailed Description
-----------------
Chronic tendonitis remains difficult to treat. Nitric oxide has been demonstrated to stimulate tenocytes to proliferate, differentiate and produce matrix components including collagen. Studies have demonstrated that nitroglycerin transdermal patches, which release nitric oxide, reduce pain and increase function in patients with chronic tendonitis. The purpose of the present study is to examine the efficacy of three dose levels of nitroglycerin, compared to placebo, in reducing pain and increasing function in patients with chronic (greater than three months' duration) lateral epicondylitis.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study of the OrthoDerm Transdermal Nitroglycerin Patch for Patients With Chronic Lateral Epicondylitis

Conditions
-----------------
Tendonitis

Intervention / Treatment
-----------------
* Drug: OrthoDerm transdermal nitroglycerin patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males >18 yr and < 70 yr BMI < 38 chronic lateral epicondylitis (symptomatic > 3 mo) pain on provocation >/- 4 on 11 point scale Exclusion Criteria: patients on other pain medications bilateral elbow pain any humerus elbow or forearm fracture or surgery signs of injury other than lateral epicondylitis any concomitant disease or pain of the upper extremity orthostatic hypotension patients taking MAO inhibitors, phosphodiesterase inhibitors, adrenergic agents pregnant or nursing women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: OrthoDerm transdermal nitroglycerin patch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain-free grip strength |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain at rest |  |  | 
| pain on provocation |  |  | 
| function |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tendonitis, nitroglycerin, nitric oxide, lateral epicondylitis
Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function

Study Overview
=================
Brief Summary
-----------------
The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension

Detailed Description
-----------------
Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension.We can accorand the pwv ,IMT and MDA to assess the impact of heart and artery structure and function.

Official Title
-----------------
The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function

Conditions
-----------------
Coronary Heart Disease, Essential Hypertension

Intervention / Treatment
-----------------
* Drug: danshen dripping pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:coronary heart disease，primary hypertension， - Exclusion Criteria:secondary hypertension，diabetes mellitus，chronic renal disease，cardiac insufficiency -

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: danshen dripping pill<br>danshen dripping pill 27mg ten pills by mouth every 8 hours for one year | Drug: danshen dripping pill<br> <br> * Other names: compound danshen dripping pill;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulse wave velocity |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ankle-brachial index |  | one year |
Temporal Pattern of Circulating DNA for Patients Receiving Irradiation

Study Overview
=================
Brief Summary
-----------------
The purpose of the research study is to test a measurement tool that will determine the radiation dose people receive when they have been accidentally exposed to radiation. This test will be done using a small amount of blood and known dose of radiation.

Official Title
-----------------
Temporal Pattern of Circulating DNA for Patients Receiving Total Body Irradiation

Conditions
-----------------
Radiation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be scheduled to undergo Total Body Irradiation (TBI) as part of a conditioning regime for a Bone Marrow Transplant. OR, Be scheduled to undergo Radiation Therapy treatment for a malignancy or other disease and have a radiation treatment field that contains at least 2 liters of tissue receiving at least 2 Gy radiation dose over the first 5 days of treatment. Patient must be willing to have blood draws as defined below. Patient must provide study-specific informed consent prior to study entry. Hemoglobin≥8. Age ≥ 18, but not older than age 60. Exclusion Criteria: Patients not meeting the above inclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Subjects receiving large volumes of Radiation
Effects of Acetaminophen on Hurt Feelings

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate whether ingestion of acetaminophen reduces the experience of hurt feelings.

Official Title
-----------------
Effects of Acetaminophen on Hurt Feelings

Conditions
-----------------
Emotional Pain

Intervention / Treatment
-----------------
* Drug: acetaminophen
* Other: cornstarch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: University of Toronto undergraduate psychology student Exclusion Criteria: Alcohol consumption (more than 2 drinks per day) Intake of enzyme-inducing drugs Prolonged fasting/eating disorders/gastroenteritis Intake of other over-the-counter or prescription analgesics Liver Disorders History of abuse treatment

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>2000 mg acetaminophen per day | Drug: acetaminophen<br>* 2 x 1000 mg doses per day<br>|
| Placebo Comparator: 2<br>2000 mg cornstarch per day | Other: cornstarch<br>* 2 x 1000 mg cornstarch per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported daily hurt feelings |  | 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reports of emotional states other than hurt feelings |  | 21 days | 
| Evaluations of self-worth |  | 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acetaminophen, Social Psychology, Affect, Interpersonal Rejection
Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique

Study Overview
=================
Brief Summary
-----------------
This study assesses the long-term results of compound tibial reconstruction treated with a microvascular latissimus dorsi flap and bone transport technique during the last 25 year in Helsinki University central Hospital.

Detailed Description
-----------------
A retrospective review of hospital records was conducted to chart the clinical and operational characteristics of patient. Patients current condition is assessed by applying two function-related (Disabilities of the Arm, Hand and Shoulder, DASH; Lower Extremity Functional Scale, LEFS) and a health-related quality of life (the 15-dimensions, 15D) questionnaires. The patients received the questionnaires by mail. A written informed consent was obtained from the participants. The obtained data was computerized and analyzed.

Official Title
-----------------
Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique: a Cross-sectional Study of Long-term Outcomes

Conditions
-----------------
Reconstructive Surgical Procedure

Intervention / Treatment
-----------------
* Procedure: Reconstructive surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 15 years. Patients with acute compound tibial fracture or sequela treated with free latissimus dorsi flap and bone transport. Exclusion Criteria: Deceased. Patients under 15 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disabilities of the Arm, Shoulder and Hand (DASH) | Assesses the function of the donor site | 10-25 years | 
| The 15-Dimensions Health-Related Quality of Life (HRQoL) instrument. | Assesses the HRQoL | 10-25 years | 
| Lower Extremity Functional Scale (LEFS) | Assesses the function of the reconstructed limb | 10-25 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
latissimus dorsi flap, bone transport, bone reconstruction, tibia, tibial fracture
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice

Official Title
-----------------
Postmarketing Surveillance Study (as Per §67(6 )AMG [German Drug Law]) of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: Atrovent®
* Drug: Ventilat®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both genders older than 40 years, who suffer from moderate or severe Chronic Obstructive Pulmonary Disease Only patients who showed following diagnosis parameters were to be considered for inclusion FEV1 (Forced expiratory volume in 1 second) and FEV1/VC (vital capacity) <70% Reversibility FEV1 <12% in the last 6 months Smoker or Ex-smoker (>10 Pack years) Asthma to be excluded Exclusion Criteria: • Contraindications listed in the Instructions for Use/Summary of Product Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic Obstructive Pulmonary Disease<br>patients receiving Atrovent® | Drug: Atrovent®<br> <br> |
| Cronic Obstructive Pulmonary Disease<br>patients receiving Ventilat® | Drug: Ventilat®<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in overall severity of the clinical picture rated on a 4-point scale |  | Up to 6 months after first study drug administration | 
| Investigator assessment of improvement of thec linical picture rated on a 6-point symptom profile |  | Up to 6 months after first study drug administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of efficacy by investigator on a 4-point scale |  | Up to 6 months after first study drug administration | 
| Assessment of efficacy by patient on a 4-point scale |  | Up to 6 months after first study drug administration | 
| Assessment of tolerability by investigator on a 4-point scale |  | Up to 6 months after first study drug administration | 
| Assessment of tolerability by patient on a 4-point scale |  | Up to 6 months after first study drug administration | 
| Number of patients with adverse drug reactions |  | Up to 6 months after first study drug administration |
Mast Cell Connect: A Registry for Patients With Mastocytosis

Study Overview
=================
Brief Summary
-----------------
The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool. No experimental intervention is involved.

Detailed Description
-----------------
Mastocytosis is an extremely rare and heterogeneous spectrum of diseases characterized by the buildup of genetically altered mast cells. Patients experience a wide range of symptoms and in some cases, mast cell buildup can lead to organ dysfunction and failure. Current treatments address disease symptoms and not the underlying cause. To facilitate the development of new therapies for mastocytosis, it is important for the community to support clinical trials and to document the impact of the disease, including disease natural history and the impact on patients, in a systematic way. Mast Cell Connect is a web-based registry that allows mastocytosis patients and caregivers to enter information about the experience of the patient living with mastocytosis directly into an online data collection tool. The Mast Cell Connect Registry allows mastocytosis patients and caregivers to enter information about the experience of the patient living with mastocytosis directly into a web-based data collection tool. Two forms of data will be collected: responses to surveys administered on the web-based portal, and de-identified data curated from medical reports uploaded by patients or their caregivers.

Official Title
-----------------
Mast Cell Connect: A Registry for Patients With Mastocytosis

Conditions
-----------------
Mastocytosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient with a diagnosis of mastocytosis, including systemic mastocytosis and cutaneous mastocytosis and any subtypes of these diseases, who is willing and able to provide written online informed consent Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Further the understanding of the epidemiology of mastocytosis and its subtypes |  | Through completion of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mastocytosis, cutaneous mastocytosis, urticaria pigmentosa, telangiectasia macularis eruptiva perstans (TMEP), diffuse cutaneous mastocytosis, solitary cutaneous mastocytosis, systemic mastocytosis, indolent systemic mastocytosis, smoldering systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease, mast cell leukemia
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Study Overview
=================
Brief Summary
-----------------
Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

Official Title
-----------------
Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Conditions
-----------------
Cystoid Macular Edema

Intervention / Treatment
-----------------
* Drug: Nepafenac 0.3%
* Drug: Saline Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens. Exclusion Criteria: previous uveitis (<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: nepafenac 0.3%<br>nepafenac 0.3% ophthalmic solution dosed once daily | Drug: Nepafenac 0.3%<br> <br> |
| Placebo Comparator: Saline Solution<br>sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily | Drug: Saline Solution<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative Clinical Findings of Cystoid Macular Edema | post-operative macular volume (mm) | 6 weeks |
Endoscopic Size Assessment of Advanced Adenomatous Polyps

Study Overview
=================
Brief Summary
-----------------
The investigators are retrospectively comparing detection rates of adenomatous polyps, advanced adenomas, and size assessment of the polyps among Rush University Medical Center endoscopists. The investigators plan to review whether the size assessment of adenomatous polyps affected the surveillance protocols and if the location of polyps detected affected the detection rates.

Official Title
-----------------
Endoscopic Size Assessment of Advanced Adenomatous Polyps; Inter Observer Variations

Conditions
-----------------
Adenoma Detection Rate Improvement in Screening Colonoscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of adenomatous polyps detected at endoscopy and diagnosed pathologically by tissue biopsy Have a colonoscopy at RUMC for screening purposes Exclusion Criteria: Failure to meet inclusion criteria Previous diagnosis of IBD or colorectal cancer

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenomatous Polyp Detection Rate | Assessing for advanced adenomas (including location). | one year | 
| Endoscopic Size Assessment Versus Pathological Size Assessment | Size of polyps at time of endoscopic procedure will be compared to the size of the same polyp by pathological assessment. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retroflexion as an indication of adenoma detection rate in colorectal cancer screening | Retroflexion is a common but not mandatory practice in colonoscopy which as not been systematically studied in terms of polyp detection. Charts will be reviewed to determine whether retroflexion was performed. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADR, Colonoscopy, Adenoma, Screening Colon Cancer
Project TEAM: Teaching HIV Prevention in the HIV Clinic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the TEAM prevention intervention delivered by a physician and an HIV-positive counselor is effective. It is hypothesized that those who receive the intervention will report a higher reduction in risky sex than those who were in the standard-care condition.

Official Title
-----------------
Project TEAM: Teaching HIV Prevention in the HIV Clinic

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Behavioral: TEAM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) 18 years or older, 2) HIV-infected, 3) Sexually active, 3)Receiving HIV primary care at participating clinic, 4) Can communicate in English or Spanish, 5) No previous enrollment in the TEAM study or intervention. Exclusion Criteria: 1) Participation in a similar study run by the TEAM PI.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: TEAM|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported unprotected (without condoms)anal or vaginal sex with HIV-negative or unknown-status persons. |  |  |